



DOCKET NO.: 2003-5213

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In Re Application of:**

**Phillip Don Cook, et al.**

**Confirmation No.: 6684**

**Application No.: 10/601,242**

**Group Art Unit: 1633**

**Filing Date: June 20, 2003**

**Examiner: Janet L. Epps Ford**

**For: GAPPED 2'-MODIFIED OLIGONUCLEOTIDES**

**EXPRESS MAIL LABEL NO: EV 817338369 US**  
**DATE OF DEPOSIT: May 22, 2006**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

- ☐ In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or

before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

- ☒ In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.116 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:

☐ Certification in Accordance with § 1.97(e) is attached; or

☒ The fee of \$180.00 as set forth in § 1.17(p) is attached.

- ☐ In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of \$180.00 as set forth in § 1.17(p).

- ☒ A copy of reference number **166 and 167-168** listed on the attached Form PTO-1449 is enclosed herewith.

- ☐ Copies of reference numbers - on the attached Form PTO 1449 are not required to be submitted pursuant to 37 CFR § 1.98(a)(2)(i).

- ☒ Copies of references **161 - 165** are not being submitted because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application number **09/951,052**, filed **September 12, 2001** for which a claim for priority under 35 U.S.C. § 120 has been made in the instant application.

- ☐ The relevance of those listed references which are not in the English language is as follows:

DOCKET NO.: ISIS-5213

- 3 -


PATENT

There are no listed references which are not in the English language.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

Date:

May 22, 2006

  
Jane E. Inglese  
Registration No. 48,444

WOODCOCK WASHBURN LLP  
One Liberty Place - 46th Floor  
Philadelphia, PA 19103  
Telephone: (215) 568-3100  
Facsimile: (215) 568-3439

© 2006 WW



<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office	Docket No. ISIS-5213	Application No. 10/601,242
	Applicant Phillip Don Cook, et al.	
	Filing Date June 20, 2003	Group 1633
	Confirmation No. 6684	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>		
	161	Dagle, J.M., et al., "Targeted degradation of mRNA in <i>Xenopus</i> oocytes and embryos directed by modified oligonucleotides: studies of An2 and cyclin in embryogenesis," <i>Nucleic Acids Res.</i> , <b>1990</b> , 18(16), 4751-4757
	162	Hayase, Y., et al., "Secondary structure in formylmethionine tRNA influences the site-directed cleavage of ribonuclease H using chimeric 2'-O-methyl oligodeoxyribonucleotides," <i>Am. Chem. Soc.</i> , <b>1990</b> , 29(37), 8793-8797
	163	Inoue, H., et al., "Studies on the recognition mode of <i>E.coli</i> RNase H using modified oligonucleotide probes," <i>Nucleic Acids Res.</i> , <b>1988</b> , <i>Symposium Series No. 20</i> , 9-10
	164	Shibahara, S., et al., "Site-directed cleavage of RNA," <i>Nucleic Acids Res.</i> , <b>1987</b> , 15(11), 4403-4415
	165	Shibahara, S., et al., "Inhibition of human immunodeficiency virus (HIV-1) replication by synthetic oligo-RNA derivatives," <i>Nucleic Acids Res.</i> , <b>1989</b> , 17(1), 239-252
	166	Tidd, et al., <i>Anti/Cancer Drug Design</i> , <b>1988</b> , 3, 117-127
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>

**Form PTO-1449 Modified**

List of Patent and Publications  
Cited by Applicant  
(Use several sheets if necessary)

U.S. Department of Commerce  
Patent and Trademark Office

Docket No.  
ISIS-5213

Application No.  
10/601,242

Applicant  
Phillip Don Cook, et al.

Filing Date  
June 20, 2003

Group  
1633

Confirmation No.  
6684

**U. S. PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Name	Class	Subclass

**FOREIGN PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO
	167	WO 91/10671 A1	07/25/91	PCT		
	168	WO 92/03568 A1	03/05/92	PCT		

**EXAMINER****DATE CONSIDERED**